



2025-2026

Respiratory Season

Surveillance and Impact

Caitlin Newhouse, MD MPH
Medical Director | Vaccine Preventable-Diseases &
Immunization Program


03/12/2026

Agenda

- Respiratory Viral Illness (RVI)
- Respiratory Syncytial Virus (RSV)
- Influenza (Flu)
- COVID-19
- Impact

Respiratory Illness Activity

Acute Respiratory Illness




Updated March 5, 2026

https://www.cdc.gov/respiratory-viruses/data/activity-levels.html#cdc_data_surveillance_section_9-level-of-respiratory-illness-activity

Season's Test Positive Trends

● COVID-19 ● Influenza ● RSV



Updated March 5, 2026


https://www.cdc.gov/respiratory-viruses/data/activity-levels.html#cdc_data_surveillance_section_9-level-of-respiratory-illness-activity



RSV

RSV Epidemic Trend


Epidemic Trend



Updated March 4, 2026

https://www.cdc.gov/respiratory-viruses/data/activity-levels.html#cdc_data_surveillance_section_9-level-of-respiratory-illness-activity

Percentage* of polymerase chain reaction test results positive for respiratory syncytial virus**, by MMWR week — National Respiratory and Enteric Virus Surveillance System, United States, July 2009–February 2026



*Weekending date for previous seasons corresponds to the week number. Surveillance season includes the 2 years running from July through June.

Report was last updated on: 2/18/2026

*All results presented are from nucleic acid amplification tests which represent >90% of the diagnostic tests reported to NREVS. The last three weeks of data in 2024-25 may be less complete. NREVS is an abbreviation for the National Respiratory and Enteric Virus Surveillance System. For more information on NREVS, please visit [National Respiratory and Enteric Virus Surveillance System | CDC](#)

**Respiratory syncytial virus types A and B are not shown separately in this report.

***The NREVS surveillance season runs from the first week in July through June of the following year.



INFLUENZA (FLU)


Preliminary* In-Season Flu Severity Assessment
for the U.S. 2025-2026 Season

(October 1, 2025, through February 28, 2026)







Moderate Severity

across all ages



Preliminary* 2025-2026 Severity Assessments (October 1, 2025, through February 28, 2026):



● Low Severity ● Moderate Severity ● High Severity ● Very High Severity


*In-season severity assessments are preliminary because the season is ongoing and influenza viruses continue to circulate. As the season progresses, severity will continue to be assessed and the classification may change. These data are also subject to revision as weekly data may not be complete due to reporting delays and backfill.

Information on intensity thresholds and classifying the severity of flu seasons can be found here: [How CDC Classifies Flu Severity | CDC](#)

All source data can be downloaded here: [Weekly U.S. Influenza Surveillance Report | CDC](#)



Influenza Positive Tests Reported to CDC by US Clinical Laboratories



Data through week ending February 28, 2026
<https://www.cdc.gov/fluview/surveillance/2026-week-08.html>

Influenza Vaccine

- Strains covered in 2025-2026
 - A/Victoria/4897/2022 (H1N1)pdm09-like virus
 - A/Croatia/10136RV/2023 (H3N2)-like virus
 - B/Austria/1359417/2021 (B/Victoria lineage)-like virus
- Next year's strain selection:
 - WHO Recommendations:
 - A/Missouri/11/2025 (H1N1)pdm09-like virus
 - A/Darwin/1454/2025 (H3N2)-like virus
 - B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus (egg-based vaccines or a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus (cell-based, recombinant, or nucleic acid based vaccines)
 - FDA VRBPAC Meeting today

Influenza Vaccine Effectiveness

- Interim report ~40% effectiveness against outpatient medical visits for H3N2 infections
 - Canada
 - 26 October 2025 - 10 January 2026
 - Test-negative design
- MMWR: 38%–41% against influenza-associated outpatient visits and 41% against influenza-associated hospitalization

Separovic Lea, et al. Interim 2025/26 influenza vaccine effectiveness estimates with immuno-epidemiological considerations for A(H3N2) subclade K protection, Canada, January 2026. Euro Surveill. 2026;31(5):pii=2600068. <https://doi.org/10.2807/1560-7917.ES.2026.31.5.2600068>



Maloney P, Reeves EL, Wielgosz K, et al. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026. MMWR Morb Mortal Wkly Rep 2026;75:116–123. DOI: <http://dx.doi.org/10.15585/mmwr.mm7509a2>.



COVID-19



COVID-19 Trends

% Test Positivity



Hospitalization Rate per 100,000 population

% ED Visits Dx'd as COVID-19



% of All Deaths in US Due to COVID-19




Data through week ending February 14, 2026

<https://www.cdc.gov/covid/php/surveillance/index.html>

Empiric Proportions and Nowcast Estimates in United States for 4-Week Periods in 2/16/2025 – 2/14/2026

Nowcast Estimates in United States for 1/18/2026 – 2/14/2026



USA			
Lineage #	Share	95%PI/CI	
XFG	29%	7–65%	
NB.1.8.1	21%	0–89%	
XFG.2.5.1	16%	8–28%	
XFG.1.1	9%	2–26%	
XFG.14.1	7%	1–26%	
XFZ	5%	0–28%	
PQ.17	4%	1–12%	
XFG.6	4%	2–9%	
XFV	2%	0–10%	
XFY	2%	0–7%	
Other	1%	1–2%	
LF.7	0%	NA	



COVID-19 Vaccine Effectiveness


- Preprint study: Pfizer COVID-19 Vaccine ~ 57% effective against emergency, urgent care
 - VA
 - September 10-November 30, 2025

Appaneal HJ et al. Early effectiveness of the BNT162b2 LP.8.1 vaccine against COVID-19 emergency department, urgent care, and outpatient visits in the US Veterans Affairs Healthcare System. medRxiv 2026.01.22.26344618; doi:



IMPACT


Emergency Visits by Age, Combined Respiratory Illness



Updated March 4, 2026

<https://www.cdc.gov/respiratory-viruses/data/most-impacted.html>


Hospitalization by Age, Combined Respiratory Illness



Updated March 5, 2026

<https://www.cdc.gov/respiratory-viruses/data/most-impacted.html>

Hospitalization by Age, Influenza




Updated March 5, 2026

<https://www.cdc.gov/respiratory-viruses/data/most-impacted.html>

Hospitalization by Age, RSV

- less than 1 year
- 1-4 years
- 5-17 years
- 18-49 years
- 50-64 years
- 65+ years



Updated March 5, 2026


<https://www.cdc.gov/respiratory-viruses/data/most-impacted.html>

Provisional Weekly COVID-19 Deaths per 100,000 Population



Data through February 7, 2026
<https://www.cdc.gov/covid/php/surveillance/index.html>


Pediatric Deaths, Age Group Breakdown by Season



Data through week ending February 28, 2026

<https://gis.cdc.gov/grasp/fluview/PedFluDeath.html>

Pediatric Deaths with underlying medical condition by season



Updated March 3, 2026

<https://gis.cdc.gov/grasp/fluview/PedFluDeath.html>



THANK YOU

Influenza 2025-2026 Season Preliminary Estimates



26,000,000
Illnesses



340,000
Hospitalizations



21,000
Deaths



90
Pediatric Deaths